Ad hoc: Biofrontera AG: Distribution Agreement with Spirit Healthcare Lim. for Ameluz® in UK and Ireland
Biofrontera AG /
Ad hoc: Biofrontera AG: Distribution Agreement with Spirit Healthcare Lim. for
Ameluz® in UK and Ireland
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Leverkusen, 24 July 2012 - Biofrontera Pharma GmbH, a fully-owned subsidiary of
Biofrontera AG, has today signed an exclusive agreement with Spirit Healthcare
Limited, Leicester, England, for the marketing of Ameluz(®) in the United
Kingdom and the Republic of Ireland. In December 2011 Ameluz(®) obtained a
centralized European approval as medicinal product for the first-line treatment
of mild and moderate actinic keratosis in the face and on the scalp.
The agreement with Spirit Healthcare will initially be valid until the end of
2016. Up to this time point Spirit Healthcare will exclusively market Ameluz(®)
in the UK and Ireland. Thereafter the financial conditions will be reviewed.
In return for exclusive marketing rights Spirit Healthcare will dedicate
significant sales resource, partly funded by Biofrontera. In addition Spirit
Healthcare will receive 20% of the revenues obtained from Ameluz(®) in the UK
and Ireland. Biofrontera will take responsibility for scientific support, the
logistics and all necessary approvals. A UK launch is anticipated in late 2012.
The agreement with Spirit Healthcare allows Biofrontera a stronger strategic
sales and marketing capability in the UK and Ireland than a normal license
contract, without the risks of building a sales force and introducing a drug to
the market.
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611
Contact:
Anke zur Mühlen
Biofrontera AG
Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290
E-mail: a.zurmuehlen@biofrontera.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via Thomson Reuters ONE
[HUG#1628959]
